Archived Newsletters
-
04.05.24 -- Process Development: Stuck In The Middle With You
4/5/2024
04/05/24 Outsourced Pharma Newsletter
-
04.04.24 -- Beyond (And Better Than) mRNA: T Cell Vaccines
4/4/2024
04/04/24 Outsourced Pharma Newsletter
-
04.03.24 -- Streamline Your Outsourcing Journey & Discover Top CDMOs
4/3/2024
04/03/24
-
04.03.24 -- How Pharma 4.0 Can Unlock The Full Potential Of External Manufacturing
4/3/2024
04/03/24 Outsourced Pharma Newsletter
-
04.02.24 -- 2024's Market Outlook For Cell & Gene Therapies
4/2/2024
04/02/24 Outsourced Pharma Newsletter
-
04.01.24 -- Understanding And Navigating Diverse Regulatory Environments
4/1/2024
04/01/24 Outsourced Pharma Newsletter
-
03.29.24 -- Outsourcing Nirvana At Eli Lilly
3/29/2024
03/29/24 Outsourced Pharma Newsletter
-
03.28.24 -- Optimizing CGT Development: Modular Approaches And Cryopreservation Insights
3/28/2024
03/28/24 Outsourced Pharma Newsletter
-
03.28.24 -- Developing Cell & Gene Therapies: Optimization-By-Design, Analytical Ultracentrifugation, Candidate Screening, And Feasibility Studies
3/28/2024
03/28/24 Outsourced Pharma Newsletter
-
03.28.24 -- Creating T Cell Vaccines In The Sands
3/28/2024
03/28/24 Outsourced Pharma Newsletter
This website uses cookies to ensure you get the best experience on our website. Learn more